Discussion Replay: Patient Advisory Boards in Clinical Research: Why and How

Patient engagement is becoming more critical than ever in successfully conducting clinical research for a drug or device in addressing patient needs and optimizing registration and reimbursement.  

The Patient Advisory Board is a key step to adequately engaging patients in product development.  Engaging these patient experts can result in better quality research and encourage decision-makers and researchers to utilize patients’ valuable input to inform clinical study protocols and ultimately enhance patient recruitment and outcomes. 

Watch the recording of this unique roundtable discussion and discuss the best practices around planning, setting up, and managing your Patient Advisory Board alongside the leading industry experts.  

What you will learn

  • What is the ideal time to set up a Patient Advisory Board in clinical research 
  • What are the best practices in the setup and management of your Patient Advisory Board
  • How to incorporate the learnings from Patient Advisory Board to the clinical trial protocol and study conduct 
Published on:
March 4, 2022

Meet the roundtable discussion participants 

Philippe Picaut – Chief Scientific Officer, AlgoTherapeutix 

Philippe is currently Chief Scientific Officer in a start-up company, AlgoTherapeutix, which aims at developing new products in complex chronic pain indications. Philippe led interdisciplinary/ international teams in different Therapeutic Areas through all phases of development including the registration of major products in the EU, USA, and Japan within six different pharmaceutical companies, Rhône-Poulenc, Rhône-Poulenc Rorer, Aventis, Pierre Fabre, Ipsen, and AlgoTherapeutix. Philippe is the co-author of more than 30 publications.

Annabel De Maria – Vice President, Patient Engagement, Alira Health 

As Patient Engagement expert, Annabel has 24 years of experience in the field of pharma and medtech. Since the start of her career, she has worked as Patient Brand Manager and Head of Communications in such companies as Pfizer, Bayer, Novartis Spain, and Nestlé Purina until she joined Alira Health in October 2020, she teaches at the Barcelona Biotechnology Institute about patient engagement, and she volunteers at the Rare Diseases Department at the Hospital Clinic of Barcelona.

The discussion will be moderated by Giulia Pierini, Consultant, Patient Engagement of Alira Health. 

Related news

Publications September 16, 2022
Considerations for Analyzing and Interpreting Data from Biometric Monitoring Technologies in Clinical Trials
The rise of technology in clinical research allows us to capture meaningful aspects of health in clinical study participants.
Biometrics Clinical eCOA
Events September 7, 2022
MDIC Annual Patient Forum 2022
We are pleased to share that we will be joining as speakers MDIC Annual Patient Forum 2022 – a key platform for the discussion of how to transform patient engagement throughout the(...)
Clinical Trials MedTech Patient Engagement
Publications September 7, 2022
The Promise and Reality of Decentralized and Hybrid Clinical Trials in Europe Today
To understand the challenges related to hybrid and decentralized trials and ways to overcome them, we spoke with Dr. Hervé Solatges, Product Management, Evidence, and Innovation (DCT(...)
Clinical Decentralized Clinical Trials Hybrid Clinical Trials
Publications September 5, 2022
Taking In-Licensed Biologics to Market: Challenges, Complexities, and Ways to Overcome Them
Taking a biologic through drug development to market is highly complex and filled with challenges. To understand these challenges, their implications and how to overcome them, we spoke(...)
Biologics Clinical Drug Development
Events August 10, 2022
We are pleased to announce that we will be sponsoring and attending DPHARM, a unique event focused on the latest innovations that modernize clinical trials.
Clinical Decentralized Clinical Trials DPHARM Patient Centric
Publications August 2, 2022
GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2
The last two years have brought forward tremendous advances in the development of prophylactic and therapeutic approaches for the treatment of SARS-CoV-2 infections.
Clinical CMC Vaccines
Multimedia May 19, 2022
Fireside Chat Replay: Latest Developments in Oncology Supportive Care
In this fireside chat, we sit down with two medical experts in oncology and discuss some of the fascinating developments that are happening in the oncology supportive care field.
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.